Gross profit margin of Sinovac Biotech Ltd. 2017-2023

Published by
Wenyi Zhang,
Sep 5, 2024

In 2023, the gross profit margin of Sinovac Biotech Ltd., one of China's leading vaccine producers, increased slightly to almost 60 percent. Thanks to the development and wide adaption of CoronaVac, the company's COVID-19 vaccine, Sinovac's annual revenue increased almost 40 times in 2021.

Gross profit margin of Sinovac Biotech Ltd. between 2017 and 2023

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

April 2024

Region

China

Survey time period

2017 to 2023

Supplementary notes

Data for years prior to 2021 come from previous annual reports.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Vaccination in France "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Vaccination in France

Global overview

6

The vaccine market: overview

4

The vaccine market: SANOFI

5

Vaccine coverage in France

8

Vaccine reluctancy

8

COVID-19: vaccine coverage

6

COVID-19: vaccine reluctancy

8

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Chinese COVID-19 vaccinesCoronavirus COVID-19 in ChinaPharmaceutical industry in ChinaVaccine industry in ChinaCoronavirus disease (COVID-19) pandemic
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.